التفاصيل البيبلوغرافية
| العنوان: |
Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology. |
| المؤلفون: |
Bannoud, Nadia, Stupirski, Juan C., Cagnoni, Alejandro J., Hockl, Pablo F., Pérez Sáez, Juan M., García, P. Alfredo, Mahmoud, Yamil D., Tudela, Julián Gambarte, Scheidegger, Marco A., Marshall, Andrea, Corrie, Pippa G., Middleton, Mark R., Mariño, Karina V., Girotti, M. Romina, Croci, Diego O., Rabinovich, Gabriel A. |
| المصدر: |
Proceedings of the National Academy of Sciences of the United States of America; 1/17/2023, Vol. 120 Issue 3, p1-11, 15p |
| مصطلحات موضوعية: |
CYTOLOGY, BEVACIZUMAB, ENDOTHELIAL cells, VASCULAR endothelial growth factors, CLINICAL trials |
| مستخلص: |
Blockade of vascular endothelial growth factor (VEGF) signaling with bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb), or with receptor tyrosine kinase inhibitors, has improved progression-free survival and, in some indications, overall survival across several types of cancers by interrupting tumor angiogenesis. However, the clinical benefit conferred by these therapies is variable, and tumors from treated patients eventually reinitiate growth. Previously we demonstrated, in mouse tumor models, that galectin-1 (Gal1), an endogenous glycan-binding protein, preserves angiogenesis in anti-VEGF-resistant tumors by co-opting the VEGF receptor (VEGFR)2 signaling pathway in the absence of VEGF. However, the relevance of these findings in clinical settings is uncertain. Here, we explored, in a cohort of melanoma patients from AVAST-M, a multicenter, open-label, randomized controlled phase 3 trial of adjuvant bevacizumab versus standard surveillance, the role of circulating plasma Gal1 as part of a compensatory mechanism that orchestrates endothelial cell programs in bevacizumab-treated melanoma patients. We found that increasing Gall levels over time in patients in the bevacizumab arm, but not in the observation arm, significantly increased their risks of recurrence and death. Remarkably, plasma Gall was functionally active as it was able to reprogram endothelial cell biology, promoting migration, tubulogenesis, and VEGFR2 phosphorylation. These effects were prevented by blockade of Gall using a newly developed fully human anti-Gall neutralizing mAb. Thus, using samples from a large-scale clinical trial from stage II and III melanoma patients, we validated the clinical relevance of Gall as a potential mechanism of resistance to bevacizumab treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Proceedings of the National Academy of Sciences of the United States of America is the property of National Academy of Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder